[ET Net News Agency, 23 December 2019] Sino Biopharmaceutical Limited (01177) said the
antithrombotic drug "Ticagrelor Tablet" developed by Chia-Tai Tianqing Pharmaceutical
Group Co., Ltd., a subsidiary of the company, has obtained approval for drug registration
granted by the National Medical Products Administration of the People's Republic of China.
The product is applicable for treating patients with acute coronary syndrome (ACS) or
patients with a history of myocardial infarction and at least one risk factor for
atherosclerotic thrombotic events, reducing the incidence of cardiovascular death,
myocardial infarction and stroke. (RC)